Skip to content

Study on Pulmonary Rehabilitation for COPD

Multidisciplinary Intervention for Improving the Health Related Quality of life in Patients with COPD

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10001009
Enrollment
Unknown
Registered
2010-09-09
Start date
2009-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

Non-multidisciplinary Intervention:Persuade strongly to quit smoke and treated with inhaled medication (Tiotropium, Fluticasone/salmeterol or combination of both)
Multidisciplinary Intervention:Disease focus education, persuade strongly to quit smoke
home or community based daily exercise supervised by telephoning
inhaled medication (Tiotropium, Fluticasone/salmeterol or combination of both)

Sponsors

Union hospital of Huazhong university of science and technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: The subject has history of chronic exposure to inhaled risk factors, such as cigarette smoke or biomass smoke, with a baseline FEV1 before bronchodilation that was 30-60% of that predicted, a prebronchodilator FEV1/FVC ratio of 70% or less, an increase of less than 10% of predicted FEV1 30 min after inhaling 300 ug salbutamol. Exclude those had respiratory disorders other than COPD.

Exclusion criteria

Exclusion criteria: Subjects who are being involved in other clinical trial; complicated with other lung and chest diseases, or/and with ischemic heart disease, or/and with cerebral vascular diseases; unable to corporate with the protocol of this study due to psychological, psychiatric disorders or diseases of the musculoskeletal system; with end-stage of this disease; unable to afford basic pharmacological treatment.

Design outcomes

Primary

MeasureTime frame
SGRQ;EELV/TLC;Borg's Index;FEV1/FVC;RV/TLC;ABparadox;FEV1%;IC;6MW;

Secondary

MeasureTime frame
Number of acute episodes during study period;AB/V;

Countries

China

Contacts

Public ContactJinnong Zhang
zjnwhhb@163.com+86 15972021289

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026